m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00364)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
PER1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5 | ||
Cell Line | NOMO-1 cell line | Homo sapiens |
Treatment: shALKBH5 NOMO-1 cells
Control: shNS NOMO-1 cells
|
GSE144968 | |
Regulation |
|
logFC: 1.46E+00 p-value: 8.91E-04 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | ALKBH5 serves as a pancreatic cancer suppressor by regulating the posttranscriptional activation of Period circadian protein homolog 1 (PER1) through m6A abolishment, which highlights a demethylation-based approach for PC diagnosis and therapy. ALKBH5 loss downregulated PER1 mRNA levels in an m6A-YTHDF2-dependent manner. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | ||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 |
BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
CFPAC-1 | Cystic fibrosis | Homo sapiens | CVCL_1119 | |
HPDE6c7 | Normal | Homo sapiens | CVCL_0P38 | |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
SW1990 | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | |
YTH domain-containing family protein 2 (YTHDF2) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by YTHDF2 | ||
Cell Line | Mouse-cerebellum granule cell | Mus musculus |
Treatment: YTHDF2 knockdown mouse-cerebellum granule cell
Control: Wild type mouse-cerebellum granule cell
|
GSE153688 | |
Regulation |
|
logFC: 1.44E+00 p-value: 9.54E-09 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | ALKBH5 serves as a pancreatic cancer suppressor by regulating the posttranscriptional activation of Period circadian protein homolog 1 (PER1) through m6A abolishment, which highlights a demethylation-based approach for PC diagnosis and therapy. ALKBH5 loss downregulated PER1 mRNA levels in an m6A-YTHDF2-dependent manner. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | ||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 |
BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
CFPAC-1 | Cystic fibrosis | Homo sapiens | CVCL_1119 | |
HPDE6c7 | Normal | Homo sapiens | CVCL_0P38 | |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
SW1990 | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | |
Pancreatic cancer [ICD-11: 2C10]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | ALKBH5 serves as a pancreatic cancer suppressor by regulating the posttranscriptional activation of Period circadian protein homolog 1 (PER1) through m6A abolishment, which highlights a demethylation-based approach for PC diagnosis and therapy. ALKBH5 loss downregulated PER1 mRNA levels in an m6A-YTHDF2-dependent manner. | |||
Responsed Disease | Pancreatic cancer [ICD-11: 2C10] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 |
BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
CFPAC-1 | Cystic fibrosis | Homo sapiens | CVCL_1119 | |
HPDE6c7 | Normal | Homo sapiens | CVCL_0P38 | |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
SW1990 | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | |
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | ALKBH5 serves as a pancreatic cancer suppressor by regulating the posttranscriptional activation of Period circadian protein homolog 1 (PER1) through m6A abolishment, which highlights a demethylation-based approach for PC diagnosis and therapy. ALKBH5 loss downregulated PER1 mRNA levels in an m6A-YTHDF2-dependent manner. | |||
Responsed Disease | Pancreatic cancer [ICD-11: 2C10] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | AsPC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 |
BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
CFPAC-1 | Cystic fibrosis | Homo sapiens | CVCL_1119 | |
HPDE6c7 | Normal | Homo sapiens | CVCL_0P38 | |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
SW1990 | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | |